Phosphatidylcholine Composition for Localized Fat Reduction With Reduced Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for localized fat reduction, such as cosmetic surgical procedures and injectable drugs like PPC with DCA, cause pain, edema, and side effects, and require intervals of at least 4 weeks between administrations, limiting their effectiveness and convenience.
Innovation Solution
A composition comprising phosphatidylcholine and glycocholic or taurocholic acid at a molar ratio of 0.7 to 3.0, administered at intervals of less than 4 weeks, effectively reduces localized fat without pain or side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If deoxycholic acid (DCA) is used as a solubilizer in PPC injection, then the fat-reducing effect is enhanced, but pain, edema, and side effects occur
Solution Approach 1:
The patent removes deoxycholic acid (DCA) from the PPC injection formulation, using PPC alone as the active ingredient. This extraction of the harmful solubilizer DCA eliminates the cell-lytic necrosis effect that causes pain and edema, while preserving the fat-reducing apoptosis effect of PPC alone
Solution Approach 2:
The patent changes the chemical composition parameters of the injection by eliminating DCA and using PPC at specific concentrations (25-50 mg/mL). This parameter change transforms the mechanism from necrosis (with pain) to apoptosis (without pain), resolving the contradiction between efficacy and side effects
2Object-affected harmful factors
If injections are administered at intervals of at least 4 weeks, then side effects are reduced, but treatment efficiency and patient convenience deteriorate
Solution Approach 1:
The patent establishes a new periodic administration schedule with intervals of 2-4 weeks (specifically 14-28 days), which is shorter than the conventional 4-week minimum. This optimized periodic action maintains safety by preventing cumulative side effects while improving treatment efficiency through more frequent fat-reducing interventions
Solution Approach 2:
The patent changes the temporal parameter of administration intervals from the conventional minimum of 4 weeks to a optimized range of 2-4 weeks. This parameter change allows more frequent treatments without compromising safety, thereby improving overall treatment efficiency and patient convenience
3Reliability
If cosmetic surgical procedures are used for fat reduction, then significant fat removal is achieved, but healing time is extended and complications occur
Solution Approach 1:
The patent replaces mechanical surgical procedures with a chemical/biological injection therapy. Instead of physically removing fat through surgery, the injection delivers PPC that triggers apoptosis of adipocytes, achieving fat reduction through biochemical mechanisms rather than mechanical intervention, thereby avoiding surgical trauma and extended healing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves significant fat reduction with improved patient convenience by allowing shorter administration intervals, reducing side effects and enhancing treatment efficacy.
Implementation Method 1
the present inventor confirmed that PPC-only composition without DCA induced apoptosis, rather than necrosis, in adipocytes, reducing only adipocytes
Implementation Method 2
a composition prepared by adding taurocholic acid (TCA), especially glycocholic acid (GCA), to phosphatidylcholine (PPC) at a specific mixing ratio
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a composition useful for reducing localized fat using phosphatidylcholine for a subject with localized fat deposits without pain, edema or side effects, and a method of administration thereof, and, more particularly, to a composition for localized fat reduction with reduced pain and side effects, comprising (i) phosphatidyl choline; and (ii) at least one selected from the group consisting of glycocholic acid (GCA), taurocholic acid (TCA) and salts thereof, wherein (i) and (ii) have a molar ratio of (ii)/(i) of 0.7 to 3.0, and wherein the composition is administered to the affected area of the subject at intervals of less than 4 weeks at a concentration of 25 to 50 mg/mL. The composition of the present invention provides a safe and stable formulation and is highly effective in reducing fat cells without various side effects, and may be administered to the affected area at shorter intervals to maximize the effects.